Former GN executive to lead Nordic expansion of AI cell-therapy company that took over Novo program

Peter Aksel Villadsen is leaving GN Hearing after six years to join Cellular Intelligence, an AI-driven cell-therapy company. He will lead the company's expansion in the Nordics. The report comes from MedWatch, and the full article is behind a subscription, so only the headline, standfirst and captions are available here.

Cellular Intelligence acquired a Parkinson's disease program from Novo Nordisk earlier this year. It also set up its European headquarters in Copenhagen. Villadsen's move is part of building up the company's presence in the region around that base.

The company is also adding two advisers. One is Jens Nielsen, CEO of BII. The other is Bob Langer, a co-founder of Moderna.

The material does not say what Villadsen's exact title will be, what the Nordic expansion will involve, or what terms applied to the Novo Nordisk program transfer. It also gives no details on the company's funding, headcount or clinical timelines.

The move matters for the Copenhagen life-science scene. A company that took over a Novo Nordisk Parkinson's program is now recruiting a senior executive from the Danish medtech sector and attracting well-known advisers from industry and academia. That suggests it intends to build a lasting European operation in Denmark rather than only hold the acquired asset.